Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers

References

• Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008;51:1403–1419.
   Google Scholar
• de Souza WA, Yugar-Toledo JC, Bergsten-Mendes G, Sabha M and Moreno H, Jr. Effect of pharmaceutical care on blood pressure control and health-related quality of life in patients with resistant hypertension. Am J Health Syst Pharm. 2007;64:1955–1961.
   PubMed Web of Science ®Google Scholar
• Martins LC, Figueiredo VN, Quinaglia T, Boer-Martins L, Yugar-Toledo JC, Martin JF, et al. Characteristics of resistant hypertension: Ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. J Hum Hypertens. 2011;25:532–538.
   PubMed Web of Science ®Google Scholar
• Acelajado MC, Pisoni R, Dudenbostel T, Dell’Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: Definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich). 2012;14:7–12.
   PubMed Web of Science ®Google Scholar
• Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens. 2009; 27:2121–2158.
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–1241.
   PubMed Web of Science ®Google Scholar
• Mahmud A and Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005; 46:1118–1122.
   PubMed Web of Science ®Google Scholar
• Chappell DC, Varner SE, Nerem RM, Medford RM and Alexander RW. Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res. 1998;82:532–539.
   PubMed Web of Science ®Google Scholar
• Bautista LE, Vera LM, Arenas IA and Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. J Hum Hypertens. 2005;19:149–154.
   PubMed Web of Science ®Google Scholar
• Mauno V, Hannu K and Esko K. Proinflammation and hypertension: A population-based study. Mediators Inflamm. 2008;2008:619704.
   PubMed Web of Science ®Google Scholar
• Salles GF, Fiszman R, Cardoso CR and Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension. 2007;50:723–728.
   PubMed Web of Science ®Google Scholar
• Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57:469–476.
   PubMed Web of Science ®Google Scholar
• Brili S, Tousoulis D, Antoniades C, Vasiliadou C, Karali M, Papageorgiou N, et al. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: A randomized cross-over study. J Am Coll Cardiol. 2008;51:742–749.
   PubMed Web of Science ®Google Scholar
• Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, et al. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension. 2006;48:1050–1057.
   PubMed Web of Science ®Google Scholar
• Takagi H, Mizuno Y, Yamamoto H, Goto SN and Umemoto T. Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: A meta-analysis of randomized controlled trials. Hypertens Res. 2012;36:368–373.
   Google Scholar
• Sackett DL, Haynes RB, Gibson ES, Hackett BC, Taylor DW, Roberts RS, et al. Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet. 1975;1:1205–1207.
   PubMed Web of Science ®Google Scholar
• Morisky DE, Green LW and Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.
   PubMed Web of Science ®Google Scholar
• Duprez DA and Cohn JN. Arterial stiffness as a risk factor for coronary atherosclerosis. Curr Atheroscler Rep. 2007; 9:139–144.
   PubMedGoogle Scholar
• Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid–femoral pulse wave velocity. J Hypertens. 2012;30:445–448.
   PubMed Web of Science ®Google Scholar
• Figueiredo VN, Yugar-Toledo JC, Martins LC, Martins LB, de Faria AP, de Haro Moraes C, et al. Vascular stiffness and endothelial dysfunction: Correlations at different levels of blood pressure. Blood Press. 2012;21:31–38.
   PubMed Web of Science ®Google Scholar
• Pabuccu T, Baris N, Ozpelit E, Akdeniz B and Guneri S. The relationship between resistant hypertension and arterial stiffness. Clin Exp Hypertens. 2012;34:57–62.
   PubMed Web of Science ®Google Scholar
• Protogerou A, Blacher J, Stergiou GS, Achimastos A and Safar ME. Blood pressure response under chronic antihypertensive drug therapy: The role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study. J Am Coll Cardiol. 2009;53:445–451.
   PubMed Web of Science ®Google Scholar
• Pietri P, Vyssoulis G, Vlachopoulos C, Zervoudaki A, Gialernios T, Aznaouridis K, et al. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens. 2006;24:2231–2238.
   PubMed Web of Science ®Google Scholar
• Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367: 1310–1320.
   PubMed Web of Science ®Google Scholar
• Magen E, Mishal J, Paskin J, Glick Z, Yosefy C, Kidon M, et al. Resistant arterial hypertension is associated with higher blood levels of complement C3 and C-reactive protein. J Clin Hypertens (Greenwich). 2008;10:677–683.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Nishimura M, Sakamoto M, Ikegaki I, Nakanishi T and Yoshimura M. Effects of interleukin-1 beta on blood pressure, sympathetic nerve activity, and pituitary endocrine functions in anesthetized rats. Am J Hypertens. 1992;5:224–229.
   PubMed Web of Science ®Google Scholar
• Ito H, Ohshima A, Tsuzuki M, Ohto N, Takao K, Hijii C, et al. Association of serum tumour necrosis factor-alpha with serum low-density lipoprotein-cholesterol and blood pressure in apparently healthy Japanese women. Clin Exp Pharmacol Physiol. 2001;28:188–192.
   PubMed Web of Science ®Google Scholar
• Filho AG, Kinote A, Pereira DJ, Renno A, dos Santos RC, Ferreira-Melo SE, et al. Infliximab prevents increased systolic blood pressure and upregulates the AKT/eNOS pathway in the aorta of spontaneously hypertensive rats. Eur J Pharmacol. 2013;700:201–209.
   PubMed Web of Science ®Google Scholar
• Rosa AC, Rattazzi L, Miglio G, Collino M and Fantozzi R. Angiotensin II induces tumor necrosis factor-alpha expression and release from cultured human podocytes. Inflamm Res. 2012;61:311–317.
   PubMed Web of Science ®Google Scholar
• Johansen NB, Vistisen D, Brunner EJ, Tabak AG, Shipley MJ, Wilkinson IB, et al. Determinants of aortic stiffness: 16-year follow-up of the Whitehall II study. PLoS One. 2012; 7:e37165.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, Aggeli C, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation. 2005;112:2193–2200.
   PubMed Web of Science ®Google Scholar
• Briet M and Schiffrin EL. Vascular actions of aldosterone. J Vasc Res. 2012;50:89–99.
   PubMed Web of Science ®Google Scholar
• Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation. 2000;102:994–999.
   PubMed Web of Science ®Google Scholar
• Tilg H, Trehu E, Atkins MB, Dinarello CA and Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83: 113–118.
   PubMed Web of Science ®Google Scholar
• Didion SP, Kinzenbaw DA, Schrader LI, Chu Y and Faraci FM. Endogenous interleukin-10 inhibits angiotensin II-induced vascular dysfunction. Hypertension. 2009;54: 619–624.
   PubMed Web of Science ®Google Scholar
• Fonseca HA, Fonseca FA, Monteiro AM, Bianco HT, Boschcov P, Brandao SA, et al. Obesity modulates the immune response to oxidized LDL in hypertensive patients. Cell Biochem Biophys. 2013.
   Google Scholar
• Moreno H, Jr., Coca A. Resistant and refractory hypertension: Reflections on pathophysiology and terminology. Blood Press. 2012;21:209–210.
   PubMed Web of Science ®Google Scholar